Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
ETA Inhibitor
Diosuxentan is a selective inhibitor of the endothelin A (ETA) receptor. It demonstrates significant biological activity in suppressing vascular responses associated with endothelin-1, making it relevant for studies investigating cardiovascular, renal, and neuroinflammatory conditions. Diosuxentan provides valuable insights for research focused on the therapeutic modulation of ETA-mediated pathways. -
Endothelin converting enzyme inhibitor
Daglutril targets the endothelin receptor, exhibiting the ability to modulate cytokine-induced endothelin-1 production in astrocytes. Its inhibitory effects on endothelin-1 generation make it a valuable research tool for screening compounds that regulate this peptide's synthesis in glial cells. This compound is particularly relevant for studies investigating the role of endothelin-1 in neuroinflammation and related neurological disorders. -
G protein-coupled receptor kinase Inhibitor
CCG 224061 is a selective inhibitor of G protein-coupled receptor kinase 2 (GRK2) with an IC50 of 0.066 μM. It effectively inhibits GRK activity in cardiomyocytes, making it a valuable tool for studying cardiac signaling pathways. This compound is particularly relevant for research focused on heart disease, heart failure, myocardial hypertrophy, and hypertension. -
GRK5 Inhibitor
CCG273441 is a selective covalent inhibitor of G protein-coupled receptor kinase 5 (GRK5), exhibiting an IC50 value of 3.8 nM. This compound demonstrates a high degree of selectivity over GRK2, with an IC50 of 4.8 μM, by targeting and covalently binding to the Cys474 residue, which is unique to the GRK5 subfamily. CCG273441 serves as a valuable tool for research into GRK5-related signaling pathways and potential therapeutic applications in various disease models. -
GRK2 Inhibitor
CCG258747 is a potent and selective inhibitor of GRK2, demonstrating an IC50 value of 18 nM and high selectivity against GRK1, GRK5, PKA, and ROCK1. This compound effectively prevents the internalization of the µ-opioid receptor (MOR) and inhibits the IgE-mediated anaphylaxis via the GRK2 and FcεRI signaling pathway, while also activating mast cells through MRGPRX2 and MRGPRB2. CCG258747 serves as a valuable tool for investigating disease mechanisms associated with GRK2 overexpression, including heart failure and opioid tolerance. -
GRK Inhibitor
GRK-IN-1 is a selective inhibitor of G protein-coupled receptor kinases (GRKs), which play a crucial role in the regulation of receptor desensitization and downregulation. This compound exhibits potential biological activity in modulating signaling pathways mediated by GPCRs, making it valuable for research focused on cardiovascular diseases, neurological disorders, and cancer. GRK-IN-1 can be utilized to investigate the impact of GRK inhibition on cellular signaling and to explore therapeutic strategies targeting GRK-related pathways. -
GRK6 Inhibitor
GRK6-IN-3 is a selective inhibitor of G protein-coupled receptor kinase 6 (GRK6), exhibiting an IC50 value of 1.03 μM. This compound modulates GRK6 activity, which is crucial for various cellular signaling pathways. GRK6-IN-3 is suitable for research applications aimed at exploring GRK6's role in receptor desensitization and its implications in various physiological and pathological processes. -
GRK5 Inhibitor
CCG-271423 is a selective inhibitor of G protein-coupled receptor kinase 5 (GRK5), demonstrating an IC50 of 2.1 nM for GRK5 and 44 μM for GRK2. This compound effectively reduces cardiomyocyte contractility and lowers calcium transient levels, making it valuable for cardiac research. Additionally, CCG-271423 features an alkyne group, enabling its use in copper-catalyzed azide-alkyne cycloaddition (CuAAc) for bioconjugation applications. -
GRK5 Inhibitor
GRK5-IN-4 is a selective covalent inhibitor of G protein-coupled receptor kinase 5 (GRK5), exhibiting an IC50 of 1.1 μM and demonstrating 90-fold selectivity over GRK2. This compound serves as a valuable tool for heart failure research by modulating GRK5 activity. Additionally, GRK5-IN-4 features an alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions, making it useful for various chemical biology applications. -
GRK6 Inhibitor
GRK6-IN-4 is a selective inhibitor of G protein-coupled receptor kinase 6 (GRK6), exhibiting an IC50 of 1.56 μM. This compound plays a crucial role in the modulation of G protein-coupled receptor signaling pathways and is relevant for research investigating hematological malignancies, inflammatory diseases, and autoimmune disorders. By inhibiting GRK6, GRK6-IN-4 provides valuable insights into the underlying mechanisms of these conditions and potential therapeutic strategies. -
GRK Inhibitor
CCG 258001 is a selective inhibitor of G protein-coupled receptor kinases (GRK), demonstrating IC50 values of 0.29 µM for GRK2, 51.8 µM for GRK1, and 33 µM for GRK5. It effectively inhibits GRK activity in cardiomyocytes and other muscle cell types, making it a valuable tool for investigating the role of GRKs in cardiac function. This compound is relevant for research into various cardiovascular conditions, including heart failure, myocardial hypertrophy, and hypertension. -
GRK Inhibitor
GRL093-22 is a potent and selective inhibitor of G protein-coupled receptor kinases (GRKs), displaying IC50 values of 60 nM for GRK5 and 40 nM for GRK6. This compound is valuable for research on mechanisms underlying heart failure and multiple myeloma, facilitating investigations into the modulation of GRK activity in these conditions. -
GRK5 Inhibitor
CCG-273463 is a selective covalent inhibitor of G protein-coupled receptor kinase 5 (GRK5), demonstrating an IC50 of 8.6 nM. This compound is instrumental in research related to heart failure, hypertrophic cardiomyopathy, and various cancer pathways. Its specificity for GRK5 makes it a valuable tool for elucidating the role of this kinase in disease mechanisms and therapeutic development. -
GRK2 Inhibitor
CCG-224406 is a selective inhibitor of G protein-coupled receptor kinase 2 (GRK2), exhibiting an IC50 of 13 nM and demonstrating over 700-fold selectivity against other GRK subfamilies, with no inhibition of ROCK1. This small molecule is suitable for research into GRK2's role in heart failure and offers a valuable tool for exploring GRK-related signaling pathways in cardiovascular biology. -
GRK5 Inhibitor
GRK5-IN-3 is a covalent inhibitor targeting G Protein-Coupled Receptor Kinase 5 (GRK5). This compound demonstrates potent inhibitory activity against GRK5 and GRK6, with IC50 values of 0.22 μM and 0.41 μM, respectively. GRK5-IN-3 is suitable for research applications focused on understanding the role of GRK5 in cellular signaling and its implications in various pathological conditions. -
GRK6 Inhibitor
GRK6-IN-5 is a selective inhibitor of G protein-coupled receptor kinase 6 (GRK6), exhibiting an IC50 of 4.48 μM. This compound is instrumental for investigating its role in hematological malignancies, inflammation-related conditions, and autoimmune disorders. Researchers can utilize GRK6-IN-5 to elucidate the biochemical pathways influenced by GRK6, potentially leading to therapeutic advancements in these diseases. -
GRK5 Inhibitor
GRK5-IN-5 is a selective inhibitor of G protein-coupled receptor kinase 5 (GRK5), demonstrating an IC50 of 0.03 μM. This compound also exhibits activity against GRK2 and GRK6, with IC50 values of 2.2 μM and 0.036 μM, respectively. GRK5-IN-5 is known for its potent activity in inhibiting myocardial hypertrophy and reducing non-myocardial cell proliferation. It effectively suppresses the upregulation of hypertrophy markers Nppa and Nppb, thereby preventing pathological remodeling of cardiac tissue. This reagent is valuable for investigating mechanisms underlying cardiac hypertrophy. -
ASM Inhibitor
KARI 201 hydrochloride is a selective inhibitor of acid sphingomyelinase (ASM) with a competitive mechanism of action, exhibiting an IC50 of 338.3 nM. This compound is capable of penetrating the blood-brain barrier and has demonstrated potential in improving neuropathological features associated with Alzheimer's disease. KARI 201 hydrochloride serves as a valuable tool for research applications focused on neurodegenerative disorders and the modulation of sphingolipid metabolism. -
ASM Inhibitor
KARI 201 is a selective, brain-penetrant competitive inhibitor of acid sphingomyelinase (ASM), exhibiting an IC50 of 338.3 nM. This compound acts as a ghrelin receptor agonist and demonstrates significant potential in ameliorating neuropathological features associated with Alzheimer's disease. KARI 201 is valuable for research investigating the modulation of ASM activity and its implications in neurodegenerative disorders. -
GLP-1R Inhibitor
GLP-1 receptor agonist 13 is a selective agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of 76 nM. This compound plays a significant role in enhancing glucose-dependent insulin secretion, thereby influencing metabolic processes. It is particularly useful in research applications focused on diabetes, obesity, and related metabolic disorders. -
GLP Inhibitor
MS012 is a selective glucagon-like peptide (GLP) inhibitor with an IC50 value of 7 nM. This compound serves as a valuable tool in the investigation of GLP dysregulation associated with various conditions, including cancer, inflammatory diseases, and neuroregenerative disorders. Its application in research may facilitate the understanding of GLP's role in these pathophysiological processes. -
Adenosine A2A Receptor Inhibitor
4-Desmethyl Istradefylline is a selective adenosine A2A receptor antagonist, serving as a significant metabolite of Istradefylline. With a Ki of 2.2 nM, it demonstrates potent inhibition of the A2A receptor, making it relevant for exploring therapeutic strategies in Parkinson's disease and related neurological disorders. Its oral bioactivity allows for convenience in in vivo research applications targeting adenosine signaling pathways. -
DAGL-α/DAGL-β Inhibitor
LEI105 is a selective and reversible dual inhibitor of diacylglycerol lipase (DAGL)-α and DAGL-β. This compound effectively decreases levels of 2-arachidonoylglycerol in Neuro2A cells, demonstrating its potential to modulate endocannabinoid signaling. Research applications include investigations into the mechanisms underlying obesity, metabolic disorders, and neuroinflammation, as well as studies of cannabinoid receptor-mediated synaptic plasticity in mouse hippocampal slices. -
TRP Channel Inhibitor
Cannabidiorcol (CBDO) is an inhibitor of transient receptor potential (TRP) channels. This compound, structurally related to cannabidiol with a shortened pentyl side chain, exhibits anti-inflammatory properties while displaying low affinity for cannabinoid receptors. Research applications include investigations into its potential role in modulating inflammation and exploring its effects on tumorigenesis at elevated concentrations. -
ACU Inhibitor/VR1 Agonist
OMDM-5 is a selective anandamide cellular uptake (ACU) inhibitor, exhibiting a Ki of 4.8 μM. In addition, OMDM-5 demonstrates potent activity as a vanilloid receptor type 1 (VR1, TRPV1) agonist, with an EC50 of 75 nM. This compound also shows weak activity as a cannabinoid receptor type 1 (CB1) ligand, with a Ki of 4.9 μM. Its properties make OMDM-5 useful for studies involving pain modulation and endocannabinoid signaling pathways. -
IBAT Inhibitor
Elobixibat hydrate is an orally active inhibitor of the intestinal bile acid transporter (IBAT), demonstrating potent activity with IC50 values of 0.53 nM for human IBAT, 0.13 nM for mouse IBAT, and 5.8 nM for canine IBAT. This compound has been shown to effectively lower LDL cholesterol levels, enhance serum GLP-1 concentrations, and promote colonic motility. Elobixibat hydrate is valuable for research applications related to chronic idiopathic constipation (CIC), dyslipidemia, non-alcoholic fatty liver disease, and the study of liver tumors, particularly in elderly populations. -
MAGL Inhibitor
OMDM169 is a selective inhibitor of monoacylglycerol lipase (MAGL), effectively increasing the levels of 2-arachidonoylglycerol (2-AG) in biological systems. This compound demonstrates significant analgesic properties through the indirect activation of cannabinoid receptors. OMDM169 exhibits an effective concentration of 0.13 μM, making it a valuable tool for research focused on pain modulation and cannabinoid receptor signaling pathways. -
HIF Inhibitor
Arylsulfonamide 64B is a potent inhibitor of hypoxia-inducible factor (HIF). This compound effectively suppresses hypoxia/HIF-mediated expression of key oncogenes such as c-Met and CXCR4, thereby demonstrating significant anti-tumor activity. Arylsulfonamide 64B is particularly relevant for research focused on uveal melanoma, as it has been shown to reduce primary tumor growth and metastasis in mouse models. -
Platelet Aggregation Inhibitor
Myrianthic acid is a pentacyclic triterpenoid that functions as a platelet aggregation inhibitor. Isolated from the root wood of Myrianthus arboreus and the leaves of Campsis grandiflora, it effectively inhibits adrenaline-induced platelet aggregation, demonstrating an IC50 of 46.2 μM. This compound is valuable for research applications focused on thrombosis and related cardiovascular disorders. -
FAAH Inhibitor
3-Decyl-5,5'-diphenyl-2-thioxo-4-imidazolidinone is a potent inhibitor of fatty acid amide hydrolase (FAAH) with a pI50 of 5.89. This compound exhibits significant activity against endocannabinoids and lipid mediators, making it relevant for studies in pain management, inflammation, and cannabinoid signaling pathways. Its limited affinity for cannabinoid receptors CB(1) and CB(2) allows for targeted research into FAAH-related physiological processes without direct receptor modulation. -
NR4A1 Inhibitor
Glycerol kinase, microorganism functions as an NR4A1 inhibitor by directly binding to and inhibiting the transcription factor NR4A1, which plays a critical role in hepatic gluconeogenesis. This inhibition leads to reduced blood glucose levels and positively influences UCP1 expression through the β-adrenergic receptor-cAMP-CREB signaling pathway, promoting the browning of white adipose tissue and enhancing thermogenesis. Additionally, it modulates intracellular fatty acid composition and energy metabolism. Research using glycerol kinase in diabetic mouse models has demonstrated its ability to counteract NR4A1-induced hyperglycemia, indicating its potential applications in diabetes and obesity studies. -
Blood Platelet Aggregation Inhibitor
Ent-8-Iso-15(S)-prostaglandin F2α is a potent inhibitor of blood platelet aggregation. This compound exhibits superior activity compared to its isomer, 8-Isoprostaglandin F2α, in whole blood assays, making it a valuable tool for studying platelet function and related cardiovascular research. Its mechanism of action can aid in the exploration of therapeutic strategies for conditions associated with abnormal platelet aggregation. -
MAO-A And 5-HT-uptake Inhibitor
Sercloremine hydrochloride is a selective and reversible inhibitor of monoamine oxidase A (MAO-A) and serotonin (5-HT) uptake. This compound is primarily utilized in research related to depression, offering insights into the modulation of serotonin levels and its effects on mood regulation. Its dual mechanism of action makes it valuable for exploring therapeutic approaches in depressive disorders. -
5-HT Reuptake Inhibitor
Clomipramine is a potent 5-HT reuptake inhibitor with an IC50 value of 1.5 nM. As a tricyclic antidepressant, it is primarily utilized in research investigating the mechanisms of depression and obsessive-compulsive disorder (OCD). Its ability to influence serotonin levels makes it a valuable tool for studying various neuropsychiatric conditions. -
5-HT/NE Reuptake Inhibitor
Dextromilnacipran is a selective serotonin and norepinephrine (5-HT/NE) reuptake inhibitor, derived from the enantiomeric form of milnacipran. This compound also functions as a human alpha-adrenergic receptor antagonist, exhibiting an IC50 value of 3.4 μM. Dextromilnacipran is primarily utilized in research applications targeting mood disorders and neuropharmacology, facilitating investigations into its psychiatric and physiological effects. -
5-HT Transporter Inhibitor
6-Nitroquipazine is a highly potent and selective inhibitor of the serotonin transporter (5-HT transporter), exhibiting a Ki value of 0.17 nM. This compound significantly impacts serotonin reuptake, making it a valuable tool for investigating the pathophysiology and treatment of psychiatric disorders, including depression. Its ability to modulate serotonin levels can be instrumental in research aimed at understanding mood regulation and therapeutic interventions in related conditions. -
Vesicular Acetylcholine Transport Inhibitor
(±)-Vesamicol hydrochloride is a potent inhibitor of vesicular acetylcholine transport, exhibiting a Ki value of 2 nM. Additionally, it demonstrates a high affinity for σ1 and σ2 receptors, with Ki values of 26 nM and 34 nM, respectively. This compound is valuable for research into cholinergic signaling and receptor interactions, facilitating studies on neurological disorders and synaptic transmission mechanisms. -
Sigma Receptor Inhibitor
KB-5492 free base is a selective inhibitor of sigma receptors, demonstrating potent activity by inhibiting specific [3H]1,3-di(2-tolyl)guanidine (DTG) binding with an IC50 of 3.15 μM. This compound exhibits anti-ulcer properties, making it valuable for research in gastrointestinal disorders and related therapeutic applications. Its mechanism of action also suggests potential implications in neuropharmacology and pain management studies. -
Sigma Receptor Inhibitor
KB-5492 anhydrous is a selective inhibitor of the sigma receptor, demonstrating inhibition of specific [3H]1,3-di(2-tolyl)guanidine (DTG) binding with an IC50 of 3.15 μM. This compound has been identified for its potential application as an anti-ulcer agent, making it relevant for research in gastrointestinal disorders and sigma receptor pharmacology. Its activity underscores the significance of sigma receptors in various biological processes, providing valuable insights for therapeutic exploration. -
S1R Inhibitor
CM304 is a potent sigma-1 receptor (S1R) inhibitor. It demonstrates significant neuroprotective effects by mitigating drug-induced convulsions in rat models. This compound is valuable for research focused on neurological disorders and the modulation of synaptic functions associated with S1R activity. -
DA/NE/5-HT Inhibitor
Tesofensine is a triple monoamine reuptake inhibitor targeting dopamine (DA), norepinephrine (NE), and serotonin (5-HT). It effectively inhibits the reuptake of these neurotransmitters in the synaptic cleft, exhibiting IC50 values of 6.5 nM for DA, 1.7 nM for NE, and 11 nM for 5-HT. Tesofensine is primarily studied for its potential as an anti-obesity agent and may be useful in related central nervous system research applications. -
β-Glucuronidase Inhibitor
β-Glucuronidase-IN-5 is a selective inhibitor of β-glucuronidase with an IC50 value of 39.8 μM. This compound demonstrates low cytotoxicity in PC-3 cells, with an IC50 greater than 30 μM, and shows no affinity for adenosine receptors A₁ and A₂A. β-Glucuronidase-IN-5 is useful for investigating diseases associated with overexpression of β-glucuronidase, including colon cancer, arthritis, and complications related to AIDS. -
PAFAH1b2/1b3 Inhibitor
P11 is a selective inhibitor of platelet-activating factor acetylhydrolases (PAFAHs) 1b2 and 1b3, demonstrating significant impairment of cancer cell survival. With IC50 values of approximately 40 nM for PAFAH1b2 and 900 nM for PAFAH1b3, P11 is a valuable tool for investigating the role of these enzymes in cancer biology and related research applications, including studies focused on cell proliferation and apoptosis. -
hSMOX Inhibitor
JNJ-1289 is a potent and selective inhibitor of human spermine oxidase (hSMOX), exhibiting a competitive and allosteric mechanism of action with an IC50 value of 50 nM. This compound is primarily utilized in research studies focused on polyamine catabolism, inflammation, and various cancer models, providing valuable insights into the role of hSMOX in these biological processes. -
Smo Inhibitor
MRT-83 hydrochloride is a potent Smoothened (Smo) receptor antagonist. By inhibiting the Hedgehog (Hh) signaling pathway and BODIPY-cyclopamine binding to human Smo, MRT-83 hydrochloride demonstrates significant biological activity. This compound is particularly relevant for research applications focused on cancer and associated signaling pathways. -
Smoothened Inhibitor
Glasdegib maleate is a potent smoothened inhibitor that selectively targets the human Smoothened (SMO) protein. With an IC50 value of 4 nM, this orally bioavailable compound effectively modulates the Hedgehog signaling pathway, making it valuable for research in cancer biology and developmental processes. Glasdegib maleate is primarily used in studies investigating tumor growth and metastasis driven by aberrant Hedgehog signaling. -
Smo Inhibitor
Glasdegib hydrochloride is a potent smoothened (SMO) inhibitor, primarily targeting the Hedgehog signaling pathway. It exhibits high affinity for human SMO, with an IC50 of 4 nM, making it an effective tool for research in cancer biology and developmental processes. This compound is valuable for studies investigating the role of SMO in tumorigenesis and therapeutic resistance in various malignancies. -
SMO Inhibitor
AZD7254 is an orally active Smoothened (SMO) inhibitor with a reported EC50 of 1.0 nM against Sonic Hedgehog (Shh) protein. This compound effectively modulates hedgehog signaling pathways, making it a valuable tool for investigating the role of SMO in various cancers and developmental disorders. Its potent inhibition of SMO activity supports research applications in targeted therapies and pathway analysis. -
SMO Inhibitor
SMO-IN-1 is an orally active Smoothened (SMO) inhibitor that demonstrates an EC50 of 89 nM for sonic hedgehog (Shh) protein. This compound is effective in disrupting the hedgehog signaling pathway, making it a valuable tool in cancer research and developmental biology studies. It may be particularly relevant for investigating tumors associated with aberrant hedgehog signaling. -
Smo Inhibitor
Saridegib hydrochloride is a selective inhibitor of Smoothened (Smo), a critical component of the Hedgehog (Hh) signaling pathway. By targeting Smo, this compound effectively disrupts Hh-mediated signaling, which is implicated in various developmental processes and diseases, including cancer. It is utilized in research to explore the role of the Hh pathway in tumorigenesis and as a potential therapeutic approach in Smo-dependent malignancies.
